Peptide Marketing, Q2 2026: Enforcement, Search Demand, and AI Visibility

How do you market a peptide therapy when the FDA keeps changing which peptides a pharmacy is even allowed to compound? In the trailing 12 months, regulators brought 5 tracked enforcement actions against peptide therapy marketing, up +400% from 1 a year earlier, while patients run about 62,413 buyer-intent searches a month. When prospective patients ask AI assistants where to get peptide therapy care, the engines named a specific provider in 47% of answers. This is the Q2 2026 edition of Authoritize’s quarterly Peptide report, covering the trailing 12 months.

By the numbers

Metric	Value
Tracked enforcement actions (all time)	9
Enforcement actions, last 12 months	5
Enforcement actions, prior 12 months	1
Year-over-year change	+400%
Peptide-adjacent actions (other categories)	32
Monthly buyer-intent searches	62,413
Average keyword difficulty (0-100)	8
AI answers naming a specific provider	47%

The Grey Zone Has a Paper Trail

Peptide therapy sits at an unusual intersection: high consumer interest, low search competition, and a regulatory foundation that can shift without warning. Most peptides reaching patients today do so through compounding pharmacies, not as federally approved finished drug products. Their legal pathway runs through the FDA’s 503A and 503B bulk-substances rules, which govern what compounders can and cannot produce. When the FDA moves a substance onto its list of materials that raise concerns for compounding, a product a clinic marketed last quarter may have no compliant sourcing pathway this quarter. BPC-157 is the clearest current example. It has been flagged as a substance of concern, yet marketing for BPC-157-containing compounds continues across the web. That gap between product status and marketing activity is precisely where enforcement starts.

The enforcement record is still short, but its trajectory is not reassuring.

Five Actions in Twelve Months Tells You Where This Is Heading

The Authoritize Atlas has tracked 9 total enforcement actions touching Peptide marketing. One of those fell in the prior 12-month window. Five fell in the trailing 12 months. That is a +400% year-over-year increase off a small base, and small-base math cuts both ways. Yes, 5 actions is not a large number in absolute terms. But the pattern in other wellness verticals, testosterone and GLP-1 among them, is that enforcement volume accelerates once regulators have established their theory of the case. The current peptide case law is giving them that.

Fines in this vertical remain rare. That is not a comfort. A single enforcement action in adjacent categories has reached six figures, and the compliance costs of responding to a warning letter, revising materials, and managing the reputational fallout routinely exceed any fine. The cost is in the tail, not the average.

Alongside those 9 direct actions, 32 additional enforcement actions hit peptide-adjacent marketing, primarily targeting research-labeled compounds like BPC-157 and sermorelin. The “research use only” and “not for human consumption” disclaimers that many peptide suppliers print on their packaging do not insulate a clinic that turns around and markets those same compounds as wellness treatments. Regulators read the full context. A clinic’s website, its email campaigns, its social posts, and its intake forms collectively constitute a marketing claim, regardless of what the supplier’s label says.

”Unsubstantiated Efficacy Claims” Is Not a Technical Term, It Is a Pattern

Among all violation categories tracked in the Atlas for this vertical, “Unsubstantiated efficacy claims” was flagged 45 times. That number is not divided evenly across 9 actions. It reflects how many individual claim instances were cited across the corpus, and the concentration signals something worth paying attention to: this is a category where the product’s mechanism sounds specific and scientific, and clinics translate that into marketing copy that overstates what the evidence supports.

The pattern is predictable. A peptide affects a biological pathway. A clinic writes that it produces a measurable, reliable outcome, or frames it as something that solves a named condition. Neither the FDA nor the FTC requires that a claim be false to be actionable. It requires that the claim be substantiated to a standard the evidence doesn’t meet. Outcome promises for unproven mechanisms, before-and-after framing that implies certainty, and statements that a protocol addresses a specific diagnosis are the three recurring triggers in the record.

The physician’s role here is not optional. Substantiation decisions belong to the clinic’s own physician. No vendor or platform takes on that responsibility. The physician who signs off on marketing claims is the physician who owns them.

What Makes Peptides Uniquely Exposed: The Sourcing Problem

Every other high-enforcement wellness vertical has at least one federally approved product anchoring the category. Testosterone therapy has approved formulations. GLP-1 drugs have approved branded products. Peptide therapy, broadly, does not. The category’s clinical use runs almost entirely through compounding, and compounding legality is not static.

The 503A and 503B frameworks give compounding pharmacies the ability to produce certain substances not available as finished drugs, but only if those substances are not on the FDA’s list of drugs that raise concerns, and only if they meet a range of other conditions. When the FDA moves BPC-157 onto a concern list, the downstream effect is not just legal, it is practical: a clinic sourcing from a compounder that is no longer operating within a compliant framework has a sourcing problem and a marketing problem simultaneously. The claim becomes harder to substantiate the moment the source becomes harder to defend.

This is what makes sourcing transparency load-bearing for peptides in a way it is not for more established verticals. A clinic should be able to articulate, in writing, where its compounds come from, that the compounder is a licensed 503A or 503B facility, and that the substances in use have not been flagged as materials of concern under current FDA guidance. That documentation is both a compliance document and the factual basis for any marketing claim about protocol quality.

62,413 Searches a Month, and the Competition Is Still Thin

The search market for peptides is real and measurable. Patients run 62,413 buyer-intent searches a month for peptide therapy terms at national scope. The average cost-per-click across those terms is $8.97, which is modest compared to testosterone or weight loss verticals. More striking is the keyword difficulty score: 8 out of 100. That is not a typo. Broadly speaking, the category has not yet attracted the kind of concentrated paid-search and SEO investment that drives keyword difficulty into the 40s and 50s for more established clinical verticals.

The window will not stay open. National telehealth platforms are already present. Defy Medical, Marek Health, and Transcend are the providers currently named by AI assistants when patients ask buyer-intent questions about peptide protocols. In an analysis of 15 AI-generated answers to those questions, 7 named a specific provider. That is 47% of answers, a share that will almost certainly grow as AI search matures and as these platforms continue to build authority.

A local or regional clinic cannot out-rank those platforms on broad national head terms. That is not a realistic goal and not a useful one. The ground that remains open is specific and local. A search for peptide therapy in a named city, for a specific protocol, or for a named practitioner is a different competitive landscape than a generic national query. The clinic that builds content around those specific terms, with accurate clinical detail reviewed by its own physician, is competing in a market the national platforms are not structured to win.

Why Compliance and Search Visibility Are the Same Project Here

Google’s quality guidelines treat health content as YMYL (Your Money or Your Life) material, held to the highest E-E-A-T standard: Experience, Expertise, Authoritativeness, and Trustworthiness. The content that ranks in that environment and the content that survives FTC scrutiny are, in practice, very similar documents. Both require named credentials, accurate mechanism descriptions, appropriate caveats, and an absence of outcome promises the evidence does not support.

Helpful, people-first content in Google’s framing means content written for a patient trying to make an informed decision, not for an algorithm and not for a conversion funnel. That framing happens to align almost exactly with what regulators expect from compliant health marketing. A page that accurately describes what a protocol involves, who is a candidate, what the sourcing and oversight process looks like, and what the current evidence does and does not show is both a defensible marketing document and a document Google is likely to treat as authoritative.

The 45 flagged instances of “Unsubstantiated efficacy claims” in the enforcement record are, at their core, failures of specificity and accuracy. The remedy is the same whether you are thinking about compliance or search: more precision, more physician review, less promotional language, more clinical detail. Those are not competing goals.

Methodology

Enforcement figures for Peptide are drawn from the Authoritize Atlas, a curated, operator-reviewed library of FDA warning letters and FTC enforcement actions in healthcare and wellness marketing. The Peptide corpus holds 9 published actions; trend comparisons use trailing-12-month windows anchored to 2026-06-30. The Atlas is keyword-gated, so it represents a meaningful sample of enforcement activity in this vertical, not a complete census.

Marketing figures are measured by Authoritize. Search demand, CPC, and keyword difficulty come from DataForSEO across 10 buyer-intent terms at United States national scope; monthly volume uses Keyword Planner where available and a clickstream estimate for terms the Planner buckets. The AI-search read runs 5 buyer questions through ChatGPT, Perplexity, and Google Gemini with web search enabled, then checks each answer against a curated list of known providers in the vertical. Because that list is curated rather than exhaustive, the share of answers naming a tracked provider is a floor, not a ceiling. Demand reflects search interest, not patient counts.

For clinics, the practical implication of both data lanes is the same. Enforcement in this category is accelerating from a low base, and AI search is beginning to route patients toward specific providers. The clinics that will compete effectively are those publishing accurate, specific, physician-reviewed content on local and protocol-specific terms, keeping every claim tied to what the evidence and the sourcing will actually support. That kind of content is the only kind that holds up in both courts simultaneously.

Frequently asked questions

How much is peptide therapy marketing enforcement growing in 2026? Regulators brought 5 tracked FDA and FTC enforcement actions against peptide therapy marketing in the trailing 12 months, up +400% from 1 a year earlier, drawn from the Authoritize Atlas.

Do AI assistants recommend specific peptide therapy providers? In a test of 15 buyer-intent questions across ChatGPT, Perplexity, and Google Gemini, the assistants named a specific provider in 47% of answers, most often national brands such as Defy Medical, Marek Health, Transcend.

How much search demand is there for peptide therapy? Patients run about 62,413 buyer-intent peptide therapy searches a month at United States national scope, at an average keyword difficulty of 8 out of 100.

What marketing violation is most common in peptide therapy? Unsubstantiated efficacy claims, flagged 45 times across peptide therapy actions in the Atlas, is the most common.

Is compliant content better for SEO and AI visibility? Yes. Google classifies health information as Your Money or Your Life (YMYL) and holds it to the highest standard of Experience, Expertise, Authoritativeness, and Trust (E-E-A-T). The accuracy and trust signals that earn search and AI visibility are the same ones that make peptide therapy content defensible to the FDA and FTC.

Where can a local peptide therapy clinic still compete? In local and specific intent: searches tied to a city, a named practitioner, or a specific protocol, where national brands are structurally weak and AI answers often name no provider at all.

Sources and further reading

• The enforcement figures come from the Authoritize Atlas, the searchable library of the FDA and FTC actions behind every number here.
• The cross-vertical picture is in the flagship State of Healthcare Marketing and Compliance; other per-vertical editions: GLP-1 and weight loss, TRT, medical spa and aesthetics.
• Screen your own pages, ads, and emails against FDA and FTC patterns with the free Claim Checker.
• Google, Search Quality Rater Guidelines (YMYL and E-E-A-T); Google Search Central, Creating Helpful, Reliable, People-First Content.
• Primary records: U.S. FDA, Warning Letters; U.S. FTC, Cases and Proceedings.